Macrophages as Potential Therapeutic Targets in Acute Myeloid Leukemia
Open Access
- 11 October 2024
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 12 (10) , 2306
Abstract
Acute myeloid leukemia (AML) is a heterogenous malignant hemopathy, and although new drugs have emerged recently, current treatment options still show limited efficacy. Therapy resistance remains a major concern due to its contribution to treatment failure, disease relapse, and increased mortality among patients. The underlying mechanisms of resistance to therapy are not fully understood, and it is crucial to address this challenge to improve therapy. Macrophages are immune cells found within the bone marrow microenvironment (BMME), of critical importance for leukemia development and progression. One defining feature of macrophages is their plasticity, which allows them to adapt to the variations in the microenvironment. While this adaptability is advantageous during wound healing, it can also be exploited in cancer scenarios. Thus, clinical and preclinical investigations that target macrophages as a therapeutic strategy appear promising. Existing research indicates that targeting macrophages could enhance the effectiveness of current AML treatments. This review addresses the importance of macrophages as therapeutic targets including relevant drugs investigated in clinical trials such as pexidartinib, magrolimab or bexmarilimab, but also provides new insights into lesser-known therapies, like macrophage receptor with a collagenous structure (MACRO) inhibitors and Toll-like receptor (TLR) agonists.Keywords
This publication has 161 references indexed in Scilit:
- Increased expression of CD70 in relapsed acute myeloid leukemia after hypomethylating agentsVirchows Archiv, 2024
- Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromesAnnals of Hematology, 2022
- Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approachCancer, 2021
- M2b macrophage polarization and its roles in diseasesJournal of Leukocyte Biology, 2018
- Alteration of cellular and immune‐related properties of bone marrow mesenchymal stem cells and macrophages by K562 chronic myeloid leukemia cell derived exosomesJournal of Cellular Physiology, 2018
- Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AMLBlood Reviews, 2018
- Aging and cancer: The role of macrophages and neutrophilsAgeing Research Reviews, 2017
- The Adenosine-Dependent Angiogenic Switch of Macrophages to an M2-Like Phenotype is Independent of Interleukin-4 Receptor Alpha (IL-4Rα) SignalingInflammation, 2013
- Prolonged subcutaneous administration of 852A, a novel systemic toll‐like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignanciesAmerican Journal of Hematology, 2012
- Role of tumor-associated macrophages in the progression of hepatocellular carcinomaSurgery Today, 2011